One-pot synthesis of isoindolinones via three-component Mannich/lactamization cascade reaction

Synthetic Communications

Volumn 42, Issue 8, 2012, Pages 1115-1127

  Zhang, Haoyi ^a   Leng, Yixin ^a   Liu, Wenjing ^a   Duan, Wenhu ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cascade reaction; Isoindolinone; Lactamization; Mannich reaction; Threecomponent

Indexed keywords

2 (2 ETHOXYLETHYL) 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 (4 METHOXYPHENYL) 3 (2 OXOBUTYL)ISOINDOLIN 1 ONE; 2 (4 METHOXYPHENYL) 3 (2 OXOHEXYL)ISOINDOLIN 1 ONE; 2 (4 METHOXYPHENYL) 6 BROMO 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 (4 METHOXYPHENYL) 6 CHLORO 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 (4 METHOXYPHENYL) 6 FLUORO 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 (4 METHOXYPHENYL) 6 HYDROXY 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 (4 METHOXYPHENYL) 6 METHOXY 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 (4 METHOXYPHENYL) 6 NITRO 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 (4 METHOXYPHENYL) 6 PHENYL 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 BENZYL 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 BUTYL 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 CYCLOHEXYL 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; 2 ISOBUTYL 3 (2 OXOPROPYL)ISOINDOLIN 1 ONE; ISOINDOLE DERIVATIVE; LACTAM; SOLVENT; TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL REACTION; DRUG SYNTHESIS; INFRARED SPECTROSCOPY; LACTAMIZATION; MANNICH REACTION; MASS SPECTROMETRY; ONE POT SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE; SOLVENT EFFECT; THIN LAYER CHROMATOGRAPHY;

EID: 84863181675     PISSN: 00397911     EISSN: 15322432     Source Type: Journal    
DOI: 10.1080/00397911.2010.535948     Document Type: Article

References (41)

1. (a) Mertens, A.; Zilch, H.; Koenig, B.; Schaefer, W.; Poll, T.; Kampe, W.; Seidel, H.; Leser, U.; Leinert, H. Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3- dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity. J. Med. Chem. 1993, 36, 2526;
2. 2 receptor antagonists: Potential atypical antipsychotic agents. J. Med. Chem. 1994, 37, 2552;
3. (c) Bishop, A. C.; Ubersax, J. A.; Shokat, K. M. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 2000, 407, 395;
4. (d) Park, J. S.; Moon, S. C.; Baik, K. U.; Cho, J. Y.; Yoo, E. S.; Byun, Y. S.; Park, M. H. Synthesis and SAR studies for the inhibition of TNF-alpha production. Part 2. 2-[3-(Cyclopentyloxy)-4-methoxyphenyl]- substituted-1- isoindolinone derivatives. Arch. Pharm. Res. 2002, 25, 137;
5. (e) Lee, S.; Shinji, C.; Ogura, K.; Shimizu, M.; Maeda, S.; Sato, M.; Yoshida, M.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 4895;
6. (f) Kanamitsu, N.; Osaki, T.; Itsuji, Y.; Yoshimura, M.; Tsujimoto, H.; Soga, M. Novel water-soluble sedative-hypnotic agents: Isoindolin-1-one derivatives. Chem. Pharm. Bull. 2007, 55, 1682;
7. (g) Hughes, T. V.; Emanuel, S. L.; O'Grady, H. R.; Connolly, P. J.; Rugg, C.; Fuentes-Pesquera, A. R.; Karnachi, P.; Alexander, R.; Middleton, S. A. 7-[1H-Indol-2- yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: Design, synthesis, and biological activity. Bioorg. Med. Chem. Lett. 2008, 18, 5130;
8. (h) Mason, K. A; Valdecanas, D.; Hunter, N. R.; Milas, L. Invest. New Drugs 2008, 26, 1.
9. (a) Hussein, Z.; Mulford, D. J.; Bopp, B. A.; Granneman, G. R. Stereoselective pharmacokinetics of pazinaclone, a new non-benzodiazepine anxiolytic, and its active metabolite in healthy subjects. Br. J. Clin. Pharmacol. 1993, 36, 357;
10. (b) Sorbera, L. A.; Leeson, P. A.; Silvestre, J.; Castaner, J. Pagoclone. Anxiolytic, GABA-A/BZD site partial agonist. Drugs of the Future 2001, 26, 651;
11. (c) Sandford, J. J.; Forshall, S.; Bell, C. Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J. Psychopharmacol. 2001, 15, 205;
12. (d) Atack, J. R.; Pike, A.; Marshall, G. 2-(4-Hydroxy-biphenyl-3-yl) isoindolin-1-one. Neuropharmacology 2006, 50, 677.
13. (a) Hajak, G. A comparative assessment of the risks and benefits of zopiclone: A review of 15 years' clinical experience. Drug Safety 1999, 21, 457;
14. (b) Bocca, M. L.; Le Doze, F.; Etard, O.; Pottier, M.; L'Hoste, J.; Denise, P. Residual effects of zolpidem 10mg and zopiclone 7.5 mg versus flunitrazepam 1mg and placebo on driving performance and ocular saccades. Psychopharmacology 1999, 143, 373;
15. (c) Carlson, J. N.; Haskew, R.; Wacker, J. Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur. J. Pharmacol. 2001, 415, 181;
16. (d) Culy, C.; Castaner, J.; Bayes, M. Eszopiclone. Drugs Future 2003, 28, 640.
17. (a) De Clercq, E. J. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491;
18. (b) Norman, M. H.; Minick, D. J.; Rigdon, G. C. Effect of linking bridge modifications on the antipsychotic profile of some phthalimide and isoindolinone derivatives. J. Med. Chem. 1996, 39, 149;
19. (c) Zhuang, Z. P.; Kung, M. P.; Mu, M. Hank, F. K. Isoindol-1-one analogues of 4-(2′- methoxyphenyl)-1-[2′-[N-(2″-pyridyl)-p- iodobenzamido]ethyl]piperazine (p-MPPI) as 5- HT1A receptor ligands. J. Med. Chem. 1998, 41, 157;
20. (d) Belliotti, T. R.; Brink, W. A.; Wise, L. D. Isoindolinone enantiomers having affinity for the dopamine D4 receptor. Bioorg. Med. Chem. Lett. 1998, 8, 1499;
21. (e) Ren, J. S.; Esnouf, R. M.; Hopkins, A. L.; Stuart, D. I.; Stammers, D. K. Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. J. Med. Chem. 1999, 42, 3845;
22. (f) Ley, S. V.; Taylor, S. J. A polymersupported [1,3,2] oxazaphospholidine for the conversion of isothiocyanates to isocyanides and their subsequent use in an ugi reaction. Bioorg. Med. Chem. Lett. 2002, 12, 1813;
23. (g) Hardcastle, I. R.; Ahmed, S. U.; Atkins, H. Isoindolinone-based inhibitors of the MDM2- p53 protein-protein interaction. Bioorg. Med. Chem. Lett. 2005, 15, 1515;
24. (h) Hardcastle, I. R.; Ahmed, S. U.; Atkins, H. Small-molecule inhibitors of the MDM2-p53 protein-protein Interaction based on an isoindolinone scaffold. J. Med. Chem. 2006, 49, 6209;
25. (i) Lee, S.; Shinji, C.; Ogura, K. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 4895.
26. (a) Campbell, J. B.; Dedinas, R. F.; Trumbower-Walsh, S. A. Addition of transientlygenerated methyl o-lithiobenzoate to imines. An isoindolone annulation. J. Org. Chem. 1996, 61, 6205;
27. (b) Couture, A.; Deniau, E.; Grandclaudon, P. LDA-induced metalation of isoindolinones. An efficient route to 3-substituted isoindoline derivatives. Tetrahedron Lett. 1998, 39, 2319;
28. (c) Deniau, E.; Enders, D. Synthesis of 3-alkyl-1-isoindolinones by alkylation of a benzotriazolyl substituted N-dimethylamino-phthalimidine. Tetrahedron 2001, 57, 2581;
29. (d) Wang, E. C.; Chen, H. F.; Hsu, M. K. A new synthesis of 3-alkyl-1- isoindolinones. Tetrahedron Lett. 2002, 43, 9163;
30. (e) Chen, M. D.; He, M. Z.; Huang, L. Q. Studies on the diastereoselective reductive alkylation of (R)-phenylglycinol derived phthalimide: Observation of stereoelectronic effects. Tetrahedron 2005, 61, 1335.
31. (a) Gai, X. J.; Grigg, R.; Khamnaen, T.; Rajviroongit, S.; Keep, A. Synthesis of 3-substituted isoindolin-1-ones via a palladium-catalysed 3-component carbonylation/amination/ Michael addition process. Tetrahedron Lett. 2003, 44, 7441;
32. (b) Kuninobu, Y.; Tokunaga, Y.; Kawata, Atsushi; Takai, K. Insertion of polar and nonpolar unsaturated molecules into carbon-rhenium bonds generated by C-H bond activation: Synthesis of phthalimidine and indene derivatives. J. Am. Chem. Soc. 2006, 128, 202;
33. (c) Grigg, R.; Sridharan, V.; Shah, M. Regioselective synthesis of N-aminoisoindolones and mono-N- and di-N,N′-substituted phthalazones utilizing hydrazine nucleophiles in a palladium-catalyzed three-component cascade process. J. Org. Chem. 2008, 73, 8352.
34. (a) Dimmock, J. R.; Sidhu, K. K.; Chen, M.; Reid, R. S.; Allen, T. M.; Kao, G. Y.; Truitt, G. A. Evaluation of some Mannich bases of cycloalkanones and related compounds for cytotoxic activity. Eur. J. Med. Chem. 1993, 28, 313;
35. (b) Traxler, P.; Trinks, U.; Buchdunger, E.; Mett, H.; Meyer, T.; Müller, M.; Regenass, U.; Rosel, J.; Lydon, N. [(Alkylamino)- methyl]acrylophenones: Potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase. J. Med. Chem. 1995, 38, 2441;
36. (c) for examples, see Juaristi, E., (Ed.). Enantioselective Synthesis of β-amino Acids; VCH: Weinheim, 1997;
37. (d) Kobayashi, S.; Ishitani, H. Catalytic enantioselective addition to imines. Chem. Rev. 1999, 99, 1069;
38. (e) Denmark, S.; Nicaise, O. J. C. Alkylation of imino groups. In Comprehensive Asymmetric Catalysis. Jacobsen, E. N.; Pfaltz, A.; Yamomoto, H. (Eds.); Springer: Berlin, 1999; Vol. 2, p. 923.
39. Arend, M.; Westerman, B.; Risch, N. Modern variants of the Mannich reaction. Angew. Chem., Int. Ed. 1998, 37, 1044.
40. (a) D'Hardemare, A. du M.; Jarjayes, O.; Mortini, F. Solvent- and catalyst-free selective Mannich reaction on catechols and parα-substituted phenols: A convenient route to catecholand phenol-iminodiacetic acid ligands. Synth. Commun. 2004, 34, 3975;
41. (b) Zhang, J. F.; Cui, Z. W.; Wang, F.; Wang, Y.; Miao, Z. W.; Chen, R. Y. Mannich type reactions of chlorophosphites, phosphoramides and aldehydes (ketones) under solvent-free and catalyst-free conditions- synthesis of N-phosphoramino a-aminophosphonates. Green Chem. 2007, 9, 1341.